Acumen Pharmaceuticals, Inc.
ABOS
$2.41
$0.010.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -104.51% | -104.01% | 30.50% | 77.00% | 78.77% |
| Gross Profit | 104.51% | 104.01% | -30.50% | -77.00% | -78.77% |
| SG&A Expenses | -7.45% | -6.29% | -5.31% | -2.23% | 1.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.48% | 8.61% | 48.78% | 87.77% | 92.49% |
| Operating Income | 9.48% | -8.61% | -48.78% | -87.77% | -92.49% |
| Income Before Tax | 2.56% | -18.57% | -63.28% | -110.69% | -107.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.56% | -18.57% | -63.28% | -110.69% | -107.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.56% | -18.57% | -63.28% | -110.69% | -107.83% |
| EBIT | 9.48% | -8.61% | -48.78% | -87.77% | -92.49% |
| EBITDA | 9.48% | -8.62% | -48.83% | -87.85% | -92.58% |
| EPS Basic | 3.92% | -17.56% | -61.05% | -103.41% | -83.07% |
| Normalized Basic EPS | 3.92% | -17.57% | -61.08% | -103.45% | -83.09% |
| EPS Diluted | 3.92% | -17.56% | -61.05% | -103.41% | -83.07% |
| Normalized Diluted EPS | 3.92% | -17.57% | -61.08% | -103.45% | -83.09% |
| Average Basic Shares Outstanding | 1.73% | 0.91% | 1.58% | 3.93% | 12.99% |
| Average Diluted Shares Outstanding | 1.73% | 0.91% | 1.58% | 3.93% | 12.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |